Impact of Intrathecal Triple Therapy Versus Intrathecal Methotrexate on Disease-Free Survival for High-Risk B-Lymphoblastic Leukemia

Journal of Clinical Oncology
07 Aug, 2020 ,

Wanda L. Salzer conducted a study to high-risk stratum of Children’s Oncology Group Study AALL1131 was designed to test the hypothesis that postinduction CNS prophylaxis with intrathecal triple therapy including methotrexate, hydrocortisone, and cytarabine would improve the postinduction 5-year disease-free survival compared with intrathecal methotrexate, when given on a modified augmented Berlin-Frankfurt-Münster backbone. The researchers concluded that postinduction CNS prophylaxis with ITT did not improve 5-year  disease-free survivalfor children with HR B-ALL.